Act-HIB Injection

Brand Name: Act-HIB
Generic: Haemophilus Influenzae Type B Vaccine (Conjugated)
Weight: 10 mcg/0.5 ml
Type: Injection
Therapeutic Class: Vaccines, Anti-sera & Immunoglobulin
Manufacturer: Sanofi Pasteur
Price: 756.00
Last Updated: 2020-11-20 18:15:00

Act-HIB Injection Uses

Act-HIB Injection contains Haemophilus Influenzae Type B Vaccine (Conjugated). Act-HIB uses:

Arthritis, Cellulitis, Haemophilus influenzae type b infection, Influenza virus vaccine, Meningitis, Septicemia

Act-HIB Injection Doses

Act-HIB Injection contains Haemophilus Influenzae Type B Vaccine (Conjugated) 10 mcg/0.5 ml. Act-HIB doses:

Primary vaccination: From 2 months: 3 injections at 1 or 2 months intervals followed by a booster 12 months after the 3rd dose.

Previously unvaccinated children between 6-12 months: 2 injections at 1 or 2 months intervals followed by a booster 12 months after the 2nd dose.

From 1-5 years: 1 single injection.


Side Effects

Irritability (72.6%), drowsiness (57.5%), tenderness (46.3%), induration (22.5%), fever (20.1%), anorexia (15.3%), diarrhea (4.4%), Pain, Sleepiness, Rash, Vomiting

Injection site erythema/ induration/ pain/ soreness/ warmth/ swelling Otitis media, URI


Haemophilus influenzae type b (Hib) bacteria are surrounded by polysaccharide capsules, which make the bacteria resistant to attack by white blood cells. However, human blood serum contains antibodies, which render the bacteria vulnerable to attack. The vaccine, which is composed of the purified polysaccharide from Hib bacterial cells, stimulates production of anticapsular antibodies and provides active immunity to the Haemophilus influenzae type b bacteria represented by the polysaccharide in the vaccine.

Haemophilus b polysaccharide vaccine, unlike the conjugate vaccine, predominantly stimulates B-cells to produce antibodies. This is known as being T-cell independent and is characteristic of polysaccharide vaccines. The initial stimulation of T-cells followed by stimulation of B cells (known as a T-cell response) is particularly important in young children to ensure adequate and persisting antibody production. Stimulation of T-cells also results in an anamnestic response to future doses of the vaccine and future natural exposure to Haemophilus influenzae type b. The poor T-cell response stimulated by the polysaccharide vaccine is thought to be one reason why the polysaccharide vaccine is not adequately immunogenic in children up to 18 months of age and may not be fully immunogenic in children 18 to 24 months of age. In addition, lack of initial T-cell stimulation probably is the reason that repeat doses of the polysaccharide vaccine do not boost the antibody response consistently.

Act-HIB Precaution

Minor illnesses such as upper respiratory infection with or without low-grade fever are not contraindications for use of HIB vaccine. As reported with Haemophilus b polysaccharide vaccines, cases of H influenzae type b disease may occur subsequent to vaccination and prior to the onset of protective effects of the vaccine. Medical supervision is needed.


Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses) may reduce the immune response to vaccine.

Pregnancy Lactation use

Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Lactation: Excretion in milk unknown



Special Warning


Acute Overdose


Interaction with other Medicine


Storage Condition


Act-HIB Injection price in Bangladesh 756.00